Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 20/20 | 0.67 |
| ▸ | RARB | P10826 | 18/20 | 0.67 |
| ▸ | RARA | P10276 | 17/20 | 0.67 |
| ▸ | RXRA | P19793 | 12/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.67 |
| ▸ | GMNN | O75496 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | THPO | P40225 | 1/20 | 0.67 |
| ▸ | MTOR | P42345 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etarotene SCHEMBL7061143 | 1.00 | RARG (0.67) | RARGRARBRARARXRAKDM4E | |
| Etarotene SCHEMBL10494236 | 1.00 | RARG (0.67) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL31097606 | 0.93 | RARG (0.57) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL11163250 | 0.93 | RARG (0.57) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7087156 | 0.92 | RARG (0.63) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL11231303 | 0.92 | RARG (0.66) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL11160612 | 0.90 | RARG (0.63) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL11160607 | 0.90 | RARG (0.63) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7552965 | 0.90 | RARG (0.63) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7552962 | 0.90 | RARG (0.63) | RARGRARBRARARXRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104588-A1 | UROLITHIN COMBINATION | AMAZENTIS SA (CH) | 2026-05-21 | — | — | WO | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20070249713-A1 | Prevention of Retinopathy by Inhibition of the Visual Cycle | LARSEN LARS M | 2007-10-25 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| EP-0625045-A4 | METHODS OF TREATING INFLAMMATORY DERMATOSES. | KLIGMAN ALBERT M (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0625045-A1 | METHODS OF TREATING INFLAMMATORY DERMATOSES | Kligman, Albert M. (US) | 1994-11-23 | — | — | EP | claimed |
| WO-1993015740-A1 | METHODS OF TREATING INFLAMMATORY DERMATOSES | KLIGMAN ALBERT M (US) | 1993-08-19 | — | — | WO | claimed |
| US-5019569-A | Topical Administritation of Retinoids | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-05-28 | — | — | US | claimed |
| EP-0379367-A2 | Method for the treatment or prevention of intrinsically aged skin with retinoids | ORTHO PHARMACEUTICAL CORPORATION (US) | 1990-07-25 | — | — | EP | claimed |
| US-4889847-A | USED IN CONJUCTION WITH A RETINOID COMPOUND | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-12-26 | — | — | US | claimed |
| US-4888342-A | APPLYING RETINOID | KLIGMAN ALBERT M (US) | 1989-12-19 | — | — | US | claimed |
| EP-0266992-A2 | Prevention of glucocorticoid-induced skin atrophy | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-05-11 | — | — | EP | claimed |
| WO-1988000466-A1 | METHODS FOR TREATMENT OF SUNDAMAGED HUMAN SKIN WITH RETINOIDS | KLIGMAN ALBERT M (US) | 1988-01-28 | — | — | WO | claimed |
| EP-0058370-B1 | TETRAHYDRONAPHTHALENE AND INDAN COMPOUNDS, THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-12-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249713-A1 | Prevention of Retinopathy by Inhibition of the Visual Cycle | VEGFA, HIF1AN, ALDH1A2 | RARG 44/4885RARB 74/4885RARA 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.